• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Glaukos Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/5/24 7:01:56 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    0001192448false00011924482024-05-302024-05-30

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 30, 2024

    Glaukos Corporation

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

        

    001-37463

        

    33-0945406

    (State or other jurisdiction

    ​

    (Commission

    ​

    (I.R.S. Employer

    of incorporation)

    ​

    File Number)

    ​

    Identification No.)

    ​

    ​

    One Glaukos Way

     

    Aliso Viejo, California

    ​

    92656

     

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (949) 367-9600

    ​

    Not Applicable

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class:

        

    Trading Symbol

        

    Name of each exchange on which registered:

    Common Stock

    ​

    GKOS

    ​

    New York Stock Exchange

    ​

    ​

    ​

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    (e) Compensatory Arrangements of Certain Officers.

    The Board of Directors (the “Board”) of Glaukos Corporation (the “Company”) previously adopted the Glaukos Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan (the “Restated Plan”), subject to stockholder approval of the Restated Plan, which amends and restates the Glaukos Corporation 2015 Omnibus Incentive Compensation Plan (the “Existing Plan”). As disclosed in Item 5.07 of this Form 8-K, the Company’s stockholders have approved the Restated Plan.

    The following summary of the terms of the Restated Plan is qualified in its entirety by reference to the text of the Restated Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

    Among other things, the Restated Plan provides for:

    (i)the reduction of the number of shares of the Company’s common stock available for award grants by approximately 7.9 million shares and provides for a new share limit that is equal to (1) 4.7 million shares, plus (2) any shares of the Company’s common Stock subject to stock options, full value awards or similar awards granted under the Existing Plan and outstanding on May 30, 2024 (with any such outstanding awards subject to performance-based vesting conditions counted at the target performance level), plus (C) shares subject to outstanding awards under the Company’s 2011 Stock Plan (the “2011 Plan”) that expire or otherwise terminate without having been exercised in full, plus (D) shares of common stock issued pursuant to awards granted under the 2011 Plan that are forfeited to or repurchased by the Company;
    (ii)an extension of the term of the Restated Plan to May 30, 2034;
    (iii)elimination of the evergreen feature;
    (iv)a prohibition on repricing of stock options and stock appreciation rights without stockholder approval; and
    (v)non-employee director compensation limits.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    The annual meeting of stockholders (the “Annual Meeting”) of Glaukos Corporation (the “Company”) was held on May 30, 2024. At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2024.

    The final voting results for each matter submitted to a vote of stockholders at the Annual Meeting are as follows:

    Proposal 1. The election of three Class III directors to hold office until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

        

    For

        

    Withheld

        

    Broker
    Non-Votes

    Thomas W. Burns

    ​

    43,130,097

    ​

    2,168,345

    ​

    2,441,003

    Marc A. Stapley

    ​

    35,495,121

    ​

    9,803,321

    ​

    2,441,003

    Leana S. Wen, M.D.

    ​

    43,596,144

    ​

    1,702,298

    ​

    2,441,003

    ​

    Proposal 2. The approval of the Glaukos Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan:

    1,369,389

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

        

    Broker
    Non-Votes

    31,369,389

    ​

    13,791,781

    ​

    137,272

    ​

    2,441,003

    ​

    Proposal 3. The non-binding advisory vote regarding the frequency of future advisory votes on the compensation of the Company’s named executive officers:

    One Year

        

    Two Years

        

    Three Years

        

    Abstain

        

    Broker
    Non-Votes

    44,213,390

    ​

    21,027

    ​

    910,086

    ​

    153,939

    ​

    2,441,003

    ​

    Proposal 4. The non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

        

    Broker
    Non-Votes

    43,205,860

    ​

    1,952,506

    ​

    140,076

    ​

    2,441,003

    ​

    Proposal 5. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024:

    1,

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

    47,458,368

    ​

    154,713

    ​

    126,364

    ​

    There were no broker non-votes on Proposal 5.

    ​

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

        

    Description

    10.1+

     

    Glaukos Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    +    Designates a management compensation plan, contract or arrangement.

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    GLAUKOS CORPORATION

    ​

    ​

    By:

    /s/ Robert L. Davis

    ​

    ​

    Name:

    Robert L. Davis

    ​

    ​

    Title:

    Senior Vice President, General Counsel & Business Development

    Date: June 5, 2024

    ​

    Get the next $GKOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    10/27/2025$120.00Equal Weight → Overweight
    Wells Fargo
    10/1/2025$103.00Buy
    Goldman
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    More analyst ratings

    $GKOS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Glaukos Corporation

    SCHEDULE 13G/A - GLAUKOS Corp (0001192448) (Subject)

    3/26/26 6:39:02 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GLAUKOS Corp (0001192448) (Filer)

    3/2/26 7:00:12 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Glaukos Corporation

    10-K - GLAUKOS Corp (0001192448) (Filer)

    2/20/26 7:54:50 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Glaukos upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Glaukos from Equal Weight to Overweight and set a new price target of $120.00

    10/27/25 8:30:13 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Glaukos with a new price target

    Goldman initiated coverage of Glaukos with a rating of Buy and set a new price target of $103.00

    10/1/25 8:52:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

    5/1/25 7:44:23 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Navratil Tomas

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/14/26 4:07:03 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Navratil Tomas

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/3/26 9:25:57 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Thurman Alex R.

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/3/26 9:22:14 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (

    4/8/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

    Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ ("Epioxa"), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated. Epioxa is now commercially available for ordering directly

    3/19/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. Net sales of $507.4 million in 2025 increased 32% yea

    2/17/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Financials

    Live finance-specific insights

    View All

    Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (

    4/8/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. Net sales of $507.4 million in 2025 increased 32% yea

    2/17/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.)

    1/20/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    12/20/21 4:15:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    3/1/21 4:10:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/14/24 3:55:55 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/13/24 5:41:34 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care